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This mini-review deals with the neuropeptide 26RFa (or QRFP) which is a member of
the RFamide peptide family discovered simultaneously by three groups in 2003. 26RFa
(or its N-extended form 43RFa) was subsequently shown to be the endogenous ligand
of the human orphan receptor GPR103. In the brain, 26RFa and GPR103mRNA are
primarily expressed in hypothalamic nuclei involved in the control of feeding behavior,
and at the periphery, the neuropeptide and its receptor are present in abundance in
the gut and the pancreatic islets, suggesting that 26RFa is involved in the regulation
of energy metabolism. Indeed, 26RFa stimulates food intake when injected centrally,
and its orexigenic effect is even more pronounced in obese animals. The expression
of 26RFa is up-regulated in the hypothalamus of obese animals, supporting that the
26RFa/GPR103 system may play a role in the development and/or maintenance of
the obese status. Recent data indicate that 26RFa is also involved in the regulation of
glucose homeostasis. 26RFa reduces glucose-induced hyperglycemia, increases insulin
sensitivity and insulinemia. Furthermore, an oral ingestion of glucose strongly stimulates
26RFa release by the gut, indicating that 26RFa is a novel incretin. Finally, 26RFa is able
to prevent pancreatic β cell death and apoptosis. This brief overview reveals that 26RFa is
a key neuropeptide in the regulation of energy metabolism. Further fields of research are
suggested including the pathophysiological implication of the 26RFa/GPR103 system.
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DISCOVERY OF 26RFa AND ITS RECEPTOR GPR103
26RFa also referred to as QRFP (for pyroglutamilated RFamide peptide) is a 26-amino acid peptide
discovered simultaneously by three different groups in 2003 including our team (Chartrel et al.,
2003; Fukusumi et al., 2003; Jiang et al., 2003). These teams have developed either a bioinformatic
approach or a comparative approach using frog brains as a source of neuropeptides (Chartrel et al.,
2002, 2003; Fukusumi et al., 2003; Jiang et al., 2003). 26RFa and/or its N-terminal extended form,
43RFa, have been subsequently biochemically characterized in the human hypothalamus and the
rat brain (Bruzzone et al., 2006; Takayasu et al., 2006), and molecular cloning has revealed that a
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26RFa precursor-encoding sequence is present in human
(Chartrel et al., 2003; Fukusumi et al., 2003), ox (Fukusumi et al.,
2003), rat (Chartrel et al., 2003; Fukusumi et al., 2003; Jiang et al.,
2003), mouse (Fukusumi et al., 2003; Jiang et al., 2003), quail
(Ukena et al., 2010), chicken (Ukena et al., 2010), and goldfish
(Liu et al., 2009), indicating that 26RFa is widely distributed
among vertebrates.
26RFa is the cognate ligand of the human orphan receptor
GPR103, also designated SP9155 or AQ27 (Chartrel et al., 2003,
2011; Jiang et al., 2003). GPR103 is a 7-transmembrane G
protein-coupled receptor (GPCR) that shares significant amino
acid identity (52%) with NPFF2 (Bonini et al., 2000; Lee et al.,
2001), another receptor for mammalian RFamide peptides.
Binding studies and functional assays indicated that the N-
elongated form of 26RFa, 43RFa, binds also with a high affinity
to GPR103 and has the same efficacy as 26RFa to inhibit cAMP
production (Fukusumi et al., 2003; Jiang et al., 2003). In contrast,
GPR103 is not activated by other mammalian RFamide peptides,
such as PrRP, RFRP-1 and -3 (Dockray, 2004), indicating that
GPR103 selectively recognizes 26RFa/43RFa. Conversely, 26RFa
displaysmoderate affinity and selectivity for NPFF-2 (Gouardères
et al., 2007). Datamining revealed that two orthologues of human
GPR103 are present in the mouse and rat genome (Kampe et al.,
2006; Takayasu et al., 2006). The two GPR103 genes from rodents
exhibit between 79 and 85% homology with human GPR103
(Kampe et al., 2006; Takayasu et al., 2006). 26RFa/43RFa bind
with a similar affinity the two forms of GPR103 in both mouse
and rat (Kampe et al., 2006; Takayasu et al., 2006). Up to now,
the occurrence of two distinct GPR103 receptors has only been
reported in rodents.
26RFa AND CONTROL OF FEEDING
BEHAVIOR
Neuroanatomical studies have revealed a discrete localization
of 26RFa-expressing neurons in various hypothalamic nuclei
including the ventromedial hypothalamic nucleus (VMH), the
lateral hypothalamic area (LHA) and the arcuate nucleus (Arc)
(Chartrel et al., 2003; Bruzzone et al., 2007). GPR103-containing
neurons are found in the same hypothalamic structures but also
in other brain nuclei, such as the piriform cortex and the nucleus
of the solitary tract (Bruzzone et al., 2007). All of these nuclei
mentioned above are known to be involved in the control feeding
behavior raising the hypothesis that 26RFa may be implicated
in the hypothalamic regulation of food intake. This is the case
as intracerebroventricular (i.c.v.) administration of 26RFa in
mice stimulates food consumption in a dose-dependent manner,
and expression of the 26RFa precursor is up-regulated in the
hypothalamus of fasted mice (Chartrel et al., 2003; Do Rego
et al., 2006; Takayasu et al., 2006). 43RFa exerts a similar effect
and is even more potent than 26RFa in stimulating appetite (Do
Rego et al., 2006; Moriya et al., 2006; Takayasu et al., 2006). In
addition, chronic administration of 43RFa for 2 weeks results
in an important increase of body weight and fat mass in mice
that also exhibit a hyperphagic behavior (Moriya et al., 2006).
These effects of 43RFa are more pronounced when mice are fed
a moderately high fat diet (Moriya et al., 2006). Finally, 26RFa
mRNAs are increased in genetically obese ob/ob and db/db mice
(Takayasu et al., 2006), suggesting that up-regulation of 26RFa
may play an important role in the maintenance of obesity.
26RFa has also been found to stimulate food intake in rats
fed a standard chow (Kampe et al., 2006; Lectez et al., 2009).
Consistent with this observation, it has been recently shown that
direct administration of 26RFa into the medial hypothalamus
increases food consumption (Zagorácz et al., 2015), and that
the concentrations of 26RFa/43RFa in the VMH are significantly
increased in rats fed a standard chow (Beck and Richy, 2009).
It has also been found that 26RFa still stimulates appetite
when rats are fed a high fat diet (Primeaux et al., 2008),
and this phenomenon is accompanied by an up-regulation of
prepro26RFa and GPR103 in the VMH and the Arc (Schreiber
et al., 2016). By contrast, these authors (Primeaux et al., 2008;
Schreiber et al., 2016) as well as Patel et al. (2008) failed to
find any effect of 26RFa or 43RFa on food consumption when
rats are fed a standard chow. Interestingly, in both mice and
rats, 26RFa potently stimulates food intake when the animals
are deprived of food for 18 h prior to the injection of the
neuropeptide (Chartrel et al., 2003; Do Rego et al., 2006; Lectez
et al., 2009) strongly suggesting that starvation potentiates the
orexigenic activity of 26RFa. To conclude, these data indicate
that in both mice and rats, 26RFa/43RFa strongly stimulate
food consumption when the animals are fed a moderate or
a high fat diet (Moriya et al., 2006; Primeaux et al., 2008),
and that the expression of prepro26RFa is enhanced in the
hypothalamus of animals submitted to such a fat diet (Moriya
et al., 2006; Primeaux et al., 2008). These data support therefore
the notion that 26RFa/43RFa plays a role in the establishment
and maintenance of the obese status in mammals. However, Beck
and Richy (2009) have recently reported a decrease of 43RFa
levels in the VMH of rats fed a high fat diet. Conversely, a single
study has investigated the expression/production of 26RFa under
chronic undernutrition (Galusca et al., 2012). This study has been
conducted in young women suffering from anorexia nervosa
in which circadian plasma 26RFa levels have been measured.
The data reveal significant higher levels of circulating 26RFa in
anorectic patients as compared to healthy volunteers, suggesting
the occurrence of an adaptive mechanism of the organism to
promote energy intake and to increase fat stores in response to
chronic undernutrition (Galusca et al., 2012).
Interestingly, it has been reported that 26RFa promotes
arousal in mice (Takayasu et al., 2006), raising the hypothesis
that the orexigenic activity of the neuropeptide may be related
to its wake-promoting effect, as previously suggested for the
other orexigenic neuropeptide orexin. However, a recent paper
reveals that, in the zebrafish, the overexpression of 26RFa in the
hypothalamus inhibits locomotor activity and promotes sleep
whereas lack of 26RFa signaling results in increased locomotor
activity and decreased sleep during the day (Chen et al., 2016).
One neuronal pathway by which 26RFa/43RFa exerts its
orexigenic activity in the hypothalamus has been elucidated.
The investigation has focused on the neuropeptide Y
(NPY)/proopiomelanocortin (POMC) system of the Arc as
a high expression of the 26RFa receptor is found in this nucleus
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(Sakurai et al., 1998; Fukusumi et al., 2003; Takayasu et al.,
2006; Bruzzone et al., 2007). i.c.v. administration of 26RFa
induces an increase in the expression and release of NPY in
the Arc and, simultaneously, a decrease in POMC expression
and α-MSH release (an anorexigenic POMC-derived peptide)
which is associated with an increase in food consumption
(Lectez et al., 2009). In addition, in this study, Lectez et al.
(2009) show that the effects of 26RFa on the activity of POMC
neurons is indirect as these neurons do not express the GPR103
transcript. Specific antagonists of the Y1 and Y5 NPY receptors
(which are expressed by POMC neurons) totally abolish the
inhibitory effect of 26RFa on POMC expression and α-MSH
release, as well as 26RFa-induced food intake, indicating that
26RFa increases consumption by stimulating the release of
NPY which in turn inhibits the activity of POMC neurons
via the activation of the Y1 and Y5 receptors (Lectez et al.,
2009, Figure 1). A possible involvement of the orexin system
in the orexigenic hypothalamic effect of 26RFa has also been
examined because the orexin system shows important similarity
with the 26RFa/GPR103 system. As a matter of fact, orexins
stimulate food intake and orexin-expressing neurons are
localized in the LHA (Sakurai et al., 1998), like 26RFa. The
orexin neurons innervate the NPY neurons of the Arc (Ciriello
et al., 2003) that express the OX-R1 receptor (Bäckberg et al.,
2002). Orexin-A stimulates the activity of NPY neurons (López
et al., 2002) and the orexigenic activity of the neuropeptide is
abolished when the animals have previously received Y1 and Y5
NPY receptor antagonists (Dube et al., 2000; Yamanaka et al.,
2000). Finally, it has been recently demonstrated that orexin
receptors and GPR103 can form functional heterodimers to
exert their effects through activation of ERK½ (Davies et al.,
2015). However, the fact that 26RFa still stimulates appetite in
orexin invalidated mice (Takayasu et al., 2006) indicates that
the orexin system is not recruited during 26RFa-induced food
intake. Alternatively, it is not known whether the OX receptor
needs to dimerise with GPR103 to initiate orexin-induced
food intake or whether orexin and 26RFa may act synergically
via heterodimerization of their receptors to potentiate their
orexigenic activities. This interesting hypothesis deserves further
investigation.
FIGURE 1 | Proposed mechanism of action of 26RFa in the hypothalamic control of food intake. 26RFa, produced by neurons of the ventromedial
hypothalamic nucleus (VMH) and the lateral hypothalamic area (LHA), stimulates the activity of NPY neurons of the arcuate nucleus (Arc) via activation of GPR103.
Subsequent NPY release in the Arc inhibits the activity of proopiomelanocortin (POMC) neurons via activation of the Y1 and Y5 receptors, leading to a stimulation of
appetite.
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In addition to its central action, accumulating data indicate
that 26RFa can also regulate energy homeostasis at the periphery.
It has notably been shown that, in the adipocyte cells 3T3-L1,
26RFa, and 43RFa stimulate triglyceride accumulation and fatty
acid uptake, and increase the expression of genes involved in lipid
uptake (Mulumba et al., 2010). Concurrently, the expression of
GPR103 is enhanced in the adipose tissue of a mouse model of
diet-induced obesity whereas that of prepro26RFa is decreased,
and the neuropeptide inhibits lipolysis in adipocytes of these
animals (Mulumba et al., 2010, 2015). It thus appears that 26RFa
plays a crucial role in the central and peripheral regulation of
body weight and energy homeostasis, and may be involved in the
development and maintenance of obesity in vertebrates.
26RFa AND CONTROL OF GLUCOSE
HOMEOSTASIS
Type 2 diabetes, which is a frequent consequence of obesity,
is characterized by chronic hyperglycemia induced by impaired
insulin secretion due to decreased β cell mass and function,
and increased insulin resistance (Butler et al., 2003; Kahn
et al., 2014). Recent studies suggest a peripheral role of
hypothalamic neuropeptides controlling feeding behavior in the
regulation of glucose homeostasis, leading to the new concept
that hypothalamic neuropeptides may serve as a link between
energy and glucose homeostasis, and identifying them therefore
as potential therapeutic targets for the treatment of diabetes
and obesity (Greenwood et al., 2011). With regard to these
observations a potential role of 26RFa/43RFa in the regulation
of glucose homeostasis has been examined. A primary study
in 2007 has investigated the effect of 26RFa on insulin and
glucagon secretion by rat perfused pancreas (Egido et al., 2007).
This study reports that 26RFa reduces glucose, arginine and
exendin-4 (a GLP-1 agonist)-induced insulin release without
affecting glucagon secretion (Egido et al., 2007). In addition,
these authors show that the inhibitory effect of 26RFa on
exendin-4-induced insulin release is not observed in pancreas
from pertussis toxin-treated rats suggesting the involvement of
a pertussis toxin-sensitive Gi protein negatively coupled to the
adenylyl cyclase system (Egido et al., 2007). Recently, the role
and mechanism of action of 26RFa/43RFa in the regulation of
glucose metabolism has been studied more thoroughly (Granata
et al., 2014; Prévost et al., 2015). The two studies show that
26RFa/43RFa and GPR103 are expressed by the pancreatic islets
as well as by the rodent insulin-secreting cell lines INS-1E
and MIN6. Granata et al. (2014) report that 26RFa and 43RFa
prevent cell death and apoptosis induced by serum starvation,
cytokines and glucolipotoxicity in INS-1E β cells and in isolated
human pancreatic islets. In addition, these authors indicate that
43RFa promotes, whereas 26RFa inhibits, glucose—and exendin-
4-induced insulin secretion through Gαs and Gαi/o proteins,
respectively (Granata et al., 2014). They also show that inhibition
of GPR103 expression by small interfering RNA in INS-1E β
cells totally blocks the insulinotropic effect of 43RFa but not the
insulinostatic action of 26RFa, suggesting that the insulinotropic
effect of 43RFa is mediated via activation of GPR103 whereas,
conversely, the insulinostatic effect of 26RFa is mediated via
another unknown receptor (Granata et al., 2014). Finally, the
same study reveals that 43RFa promotes glucose uptake by β cells
whereas 26RFa does not (Granata et al., 2014).
Our team has also investigated the role and mechanism of
action of 26RFa in the regulation of glucose homeostasis (Prévost
et al., 2015). Clinical studies performed in human revealed a
positive correlation between plasma 26RFa and plasma insulin
in obese, type 2 diabetic patients and healthy volunteers. In
addition, measurement of plasma 26RFa during an oral glucose
tolerance test shows an increase in the circulating levels of the
neuropeptide during the test, indicating a link between the 26RFa
system and glucose homeostasis (Prévost et al., 2015). Finally,
immunohistochemical experiments describe the presence, in
abundance, of 26RFa in the gut, from the stomach to the colon,
suggesting that the gut is the primary source of circulating
26RFa that can be released under an oral glucose load. In mice,
it was found that i.p. administration of 26RFa does not alter
basal glycemia. In contrast, the neuropeptide strongly attenuates
glucose-induced hyperglycemia during a glucose tolerance test,
indicating that the neuropeptide exerts an antihyperglycemic
effect rather than a hypoglycemic effect. In addition, it is reported
that 26RFa enhances insulin sensitivity and increases insulin
FIGURE 2 | Proposed mechanism of action of 26RFa in the control of
glucose homeostasis. 26RFa is abundantly produced by the gut and
released in the general circulation after an oral glucose load. 26RFa stimulates
insulin release by pancreatic cells and potentiates insulin sensitivity on target
tissues (muscle, adipose tissue), leading to a decrease of glycemia.
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production, suggesting that the two mechanisms contribute to
the antihyperglycemic effect of 26RFa. 26RFa-induced insulin
production is due to a direct action of the neuropeptide on
pancreatic β cells as 26RFa stimulates insulin release by theMIN6
cells that express GPR103, and as invalidation of GPR103 in these
cells totally abolishes 26RFa-induced insulin secretion (Prévost
et al., 2015). These observations are partially in agreement with
those of Granata et al. (2014) reporting that 43RFa stimulates
insulin secretion by human pancreatic islets and INS-1E β cells
by activating GPR103. However, the same authors found that
26RFa exerts an opposite effect to that of 43RFa, and that the
inhibiting effect of 26RFa on insulin secretion is not mediated
by GPR103. They thus suggest that NPFF2, another receptor that
26RFa can bind to but with a much lower affinity than to GPR103
(Moriya et al., 2006), may be involved in the insulinostatic activity
of 26RFa. In our study (Prévost et al., 2015), we show that MIN6
cells do not express NPFF2 that might explain the discrepancy
between the two studies.
26RFa has also been found to increase insulin sensitivity and
GPR103 is co-expressed with the insulin receptor and the glucose
transporter, GLUT-4, in the muscle, liver and adipose tissue
(Prévost et al., 2015). In addition, a recent study indicates that
26RFa enhances insulin’s effects on glucose uptake in rat skeletal
muscle cells (Allerton and Primeaux, 2015). Altogether, these
observations strongly suggest a direct action of the neuropeptide
on insulin target tissues. Finally, it has been observed that an oral
ingestion of glucose induces an increase in plasma 26RFa levels
30 min after the glucose load, whereas this phenomenon is not
observed when glucose is administrated i.v., indicating therefore
that elevation of 26RFa in the blood is due to a massive release of
the neuropeptide by the gut (Prévost et al., 2015). In conclusion,
these studies promote evidence for an important role of 26RFa,
acting as an incretin, in the regulation of glucose homeostasis
(Figure 2). Interestingly, a genome wide identification of new
genes causing type 1 diabetes with autoimmune thyroiditis has
revealed a strong association of the GPR103 gene with this
pathology (Tomer et al., 2015), supporting the involvement of the
26RFa/GPR103 system in the regulation of glucose metabolism.
CONCLUSION
Accumulating data obtained during the last decade reveal that the
26RFa/GPR103 system plays an important role in the regulation
of food intake and glucose homeostasis. Obesity associated with
type 2 diabetes is a major world-wide problem of public health
as 11% of the world population is obese (Organisation Mondiale
de la Santé, 2016) and 400 millions people are affected by type
2 diabetes in the world (Kahn et al., 2014). One main axis for
further research would be to investigate whether dysfunction
of the 26RFa/GPR103 system is associated with diabetes/obesity
that could serve as a basis to develop 26RFa analogs to treat
the pathology. Supporting this idea, it can be reminded that,
during the last decade, the therapeutic arsenal to treat type
2 diabetes has been enlarged with the occurrence of novel
classes of drugs, such as GLP-1 agonists and inhibitors of
DPPIV.
Besides, an increasing body of evidence supports
the existence in the hypothalamus of a glucoregulatory
system that acts coordinately with pancreatic islets to
regulate blood glucose levels, via both insulin-dependent
and insulin-independent mechanisms, that would be
responsible of 50% of glucose homeostasis. Considering
this latter observation, it would be important to investigate
whether the hypothalamic neuronal populations expressing
26RFa are involved in the central regulation of glucose
homeostasis.
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